Kasturba Medical College, India Wins XV Fujio Cup Quiz in NCRM NICHE 2020
19.10.2020 10:55:00 EEST | Business Wire | Press release
Sufyan Ibrahim and Himanshu Yashavanthi Nagesh of Kasturba Medical College, India, won the prestigious Fujio Cup Quiz (FCQ), an active knowledge gaining academic event of NCRM NICHE 2020, on stem cells and regenerative medicine, in a toughly fought contest among teams representing Monash University, Australia, Birla Institute of Technology (BITS-Pilani), India and Bandung Institute of Technology, Indonesia, who came second. The virtual event had lectures by Prof. Masaharu Seno, Okayama University on induced pluripotent stem cells, Dr Maria Nostro, University of Toronto on pancreatic progenitors for diabetes and Fr Francis Xavier, Loyola College, Chennai in the inter-disciplinary conclave on stress management during Covid-19.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201019005298/en/
Winners of XV Fujio Cup Quiz, Dr. Ibrahim and Mr. Nagesh of Kasturba Medical College, India, with the 2020- Joyce and James Till Travel Grant Awardee, Dr. Natarajan, a 2013- FCQ Elite. (Graphic: Business Wire)
Regenerative Medicine is a specialty demanding inter-disciplinary interaction, as physical forces like gravity and elasticity, chemically synthesized polymers and nanomaterial scaffolds, provide suitable micro environment to the cells for in vitro culture in the lab, which are transplanted to replace, restore, repair and regenerate tissues to address organ failures. FCQ, a part of NCRM NICHE started in 2006 is conducted in Tokyo, Japan, since 2017 in which young scholars of different specialties of science from all over the world participate, cross several steps of quizzing and assignments to win the trophy. Alumni of top scoring teams of FCQ (FCQ elites) are eligible to nominate candidates to Edogawa NICHE Prize (www.edogawanicheprize.org). The Joyce and James Till Travel Grant (www.j2t2grant.org) instituted in 2018, with a grant by Prof. James Till, 2018 Edogawa NICHE Prize recipient, was awarded this year to Dr. Rupesh Kumar Natarajan, (2013 FCQ elite), now pursuing fellowship in pediatric cardiology, University of Minnesota, USA.
FCQ as an innovation platform, has started attracting multinational companies for collaboration following development of novel solutions like BEES-HAUS for urethral stricture (https://onlinelibrary.wiley.com/doi/full/10.1111/iju.13852), cartilage repair (https://www.sciencedirect.com/science/article/pii/S2352320420300274) and the recently granted patent on microgravity based enhancement of nitric oxide synthesis by blood cells, specially NK cells.
Dr. Shojiro Katoh, (Founder, EELS) congratulated the winners and hopes to invite to Japan beside honoring the 2020 Edogawa NICHE Prize recipient Dr. John Venter in the coming years, by when the Boron Neutron Capture Therapy (BNCT) in Edogawa Hospital (http://bnct-cancer.com/center.php) could be ready to offer treatment to cancer patients from abroad and start research collaboration with overseas institutes. Event information will be updated in: www.ncrmniche.org
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201019005298/en/
Contact information
Samuel JK Abraham
info@gncorporation.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Newmont Announces Key Executive Appointments for the Next Phase of Delivery16.6.2026 00:20:00 EEST | Press release
Newmont Corporation (NYSE: NEM, ASX: NEM, PNGX: NEM) (“Newmont”) today announced leadership appointments that further shape its go-forward Executive Leadership Team under President and Chief Executive Officer Natascha Viljoen and reflect the depth of leadership talent within the company. Effective July 1, 2026, Brian Tabolt has been appointed Chief Financial Officer, Mark Rodgers has been appointed Chief Operating Officer, and David Thornton has been appointed Chief Technical Officer. In addition, David Fry has been promoted to Executive Vice President, Project Development, reflecting the importance of disciplined project development and execution as Newmont advances its highest-return growth opportunities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615487768/en/ Mark Rodgers - COO “These appointments bring together respected leaders with deep industry experience and a strong understanding of our operational, financia
Westlake Expands Global Chlorovinyls Manufacturing Capacity With Acquisition of PVC and VCM Plants in Wilhelmshaven, Germany15.6.2026 21:18:00 EEST | Press release
Westlake Corporation (NYSE: WLK) (“Westlake”) announced today that its German subsidiary, Westlake Vinnolit GmbH & Co. KG, has completed the previously-announced acquisition of a polyvinyl chloride and vinyl chloride monomer production site located in Wilhelmshaven, Germany (the “Wilhelmshaven plant”). The Wilhelmshaven plant, which was previously in insolvency administration, has the capacity to produce 380,000 metric tons of PVC per year. “This acquisition strengthens our Performance & Essential Materials business by expanding our global chlorovinyls manufacturing footprint and complements our existing chlorovinyl production facilities in Europe and North America,” said Jean-Marc Gilson, President and Chief Executive Officer of Westlake. “The Wilhelmshaven plant, which is located in Lower Saxony on Germany’s North Sea coast, benefits from advantageous logistical infrastructure, including a deep-water dock that enables efficient raw-materials supply. We look forward to welcoming the s
Onera Announces Integration of the Onera hPSG® Solution With Somnoware15.6.2026 20:35:00 EEST | Press release
Onera Health, a leader in transforming sleep medicine, announces that its end-to-end home polysomnography solution, the Onera hPSG® solution, now integrates with Somnoware by ResMed sleep lab management software. This integration enables clinicians to conduct Polysomnography tests (PSGs) where patients sleep most comfortably, in their own home, while managing the entire workflow in Somnoware. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615106079/en/ Onera hPSG®, an end-to-end home polysomnography solution from Onera Health, is now integrated into Somnoware, enabling their shared customers to conduct Polysomnography tests (PSGs) in the patient's home while managing the entire workflow in Somnoware. “The integration with Somnoware is a welcomed enhancement that broadens access to the Onera hPSG® solution,” states Ruben de Francisco, Founder and CEO of Onera Health. “Many sleep centers are customers of both Onera and Somn
Digital Cooperation Organization Launches Global Expert Community to Accelerate International Digital Cooperation15.6.2026 19:18:00 EEST | Press release
The Digital Cooperation Organization (DCO), the world's first standalone international organization dedicated to inclusive and sustainable digital economy growth, today announced the launch of the Global Expert Community (GEC) — a new platform designed to mobilize expertise and advance international collaboration in support of high-impact digital initiatives across DCO Member States and beyond. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615565781/en/ Digital Cooperation Organization Launches Global Expert Community to Accelerate International Digital Cooperation (Graphic: AETOSWire) The GEC reflects the DCO's continued commitment to turning digital cooperation into action by expanding access to specialized expertise and strengthening collaboration across sectors and borders. As digital transformation reshapes economies and societies worldwide, the Community is designed to convert global perspectives and practical expe
New Pivotal Study Data Show Takeda’s Oveporexton Improved Daily Function, Cognition and Nighttime Sleep for People with Narcolepsy Type 115.6.2026 19:00:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK)today presented additional results from two pivotal studies at SLEEP 2026, showing oveporexton (TAK-861), an oral orexin receptor 2 (OX2R)-selective agonist, improved daily functioning as well as cognitive and sleep-related symptoms associated with narcolepsy type 1 (NT1).1,2,3 Oveporexton is designed to address the underlying orexin deficiency that causes NT1 by restoring orexin signaling. These data, along with previously disclosed Phase 3 results, demonstrated improvement across the broad disease spectrum, supporting the potential of oveporexton to redefine the standard of care for NT1.4 "Narcolepsy type 1 is a 24-hour disease driven by orexin deficiency, and while excessive daytime sleepiness and cataplexy are the most recognized symptoms, many people experience additional bothersome symptoms such as cognitive difficulties and disrupted nighttime sleep," said Emmanuel Mignot, M.D., Ph.D., principal investigator for the FirstLight (TAK-861-3001) Phase 3 stu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom